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ABSTRACT The	immune	system	has	evolved	to	protect	us	from	infectious	disease	and	not	to	overreact	to	our	own	tissues	or	commensal	flora.	Immune	system	attack	directed	against	self-tissue	is	referred	to	as	autoimmune	disease,	a	group	of	diseases	that	affect	more	than	5%	of	the	population.	Hypothyroidism	and	type	1	diabetes	are	well-known	examples,	resulting	from	the	destruction	of	the	thyroid	gland,	and	of	the	insulin-producing	beta	cells	in	the	pancreatic	islets,	respectively.	Autoimmunity	is	also	the	predominant	cause	of	primary	adrenal	failure,	known	as	Addison’s	disease,	where	the	adrenal	cortex	is	destroyed	by	the	immune	system.	All	four	studies	in	this	thesis	were	aimed	to	improve	our	understanding	of	autoimmune	disease	in	terms	of	genetic	risk	factors,	serological	biomarkers,	and	tolerance	mechanisms.	Despite	its	high	heritability,	little	is	known	about	the	genetic	background	of	Addison’s	disease.	Paper	I	and	II	address	the	heritable	risk	factors	in	Addison’s	disease	and	discover	novel	genetic	risk	variants.	Early	recognition	of	the	rare	syndrome	autoimmune	polyendocrine	syndrome	type	I	(APS1)	is	essential	for	prevention	of	its	potentially	lethal	complications.	By	identifying	four	previously	undiagnosed	patients	with	APS1,	Paper	III	is	a	proof-of-concept	study	showing	that	serological	screening	of	patients	with	Addison’s	disease	can	identify	otherwise	undiagnosed	APS1	patients.	Paper	IV	studies	peripheral	immune	tolerance	by	investigating	the	serologic	repertoire	in	patients	with	mutations	in	FOXP3,	lacking	regulatory	T	lymphocytes.	Autoantibodies	against	a	set	of	structurally	unrelated	enterocyte	antigens	are	demonstrated,	including	tissue-specific	nuclear	receptors.	In	summary,	this	thesis	takes	on	several	aspects	of	autoimmunity.	Both	genetic,	serological	and	clinical	studies	are	integrated	to	explore	new	characteristics	of	tissue-specific	autoimmune	disease.			  
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AA Alopecia areata 
AAD Autoimmune Addison's disease 
ACTH Adrenocorticotropic hormone 
AIHA Autoimmune haemolytic anaemia 
AIRE Autoimmune regulator 
AITD Autoimmune thyroid disease 
APS1 Autoimmune polyendocrine syndrome type 1 
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BACH2 BTB Domain And CNC Homolog 2 
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CoD Coeliac disease 
CTLA4 Cytotoxic T-lymphocyte-associated protein 4 
CYP27B1 Cytochrome P450 Family 27 Subfamily B Member 1 
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EDTA Ethylenediaminetetraacetic acid 
eQTL Expression quantitative trait locus 
FAS Fas cell surface death receptor 
FOXP3 Forkhead box P3 
GWAS Genome-wide association study 
HLA Human leukocyte antigen 
IgG Immunoglobulin G 
IL2RA Interleukin 2 receptor subunit alpha 
IPEX Immunodysregulation, polyendocrinopathy, and enteropathy, X-linked 
ITCH Itchy E3 ubiquitin protein ligase 
JIA Juvenile idiopathic arthritis 
LRBA LPS responsive beige-like anchor protein 
MG Myasthenia gravis 
MHC Major histocompatibility complex 
MS Multiple sclerosis 
NLRP1 NLR family pyrin domain containing 1  
NOD2 Nucleotide binding oligomerization domain containing 2 
PBC Primary biliary cirrhosis 
PCR Polymerase chain reaction 
PSO Psoriasis 
PTPN22 Protein tyrosine phosphatase, non-receptor type 22 
QTL Quantitative trait locus 
  
RA Rheumatoid arthritis 
RAG Recombination-activating genes 
RNA Ribonucleic acid 
SLE Systemic lupus erythematosus 
SNP Single-nucleotide polymorphism 
SS Sjögren's syndrome 
STAT Signal transducer and activator of transcription 
T1DM Type 1 diabetes mellitus 
TSH Thyroid-stimulating hormone 
UC Ulcerative colitis 
UTR Untranslated region 
VIT Vitiligo 	
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INTRODUCTION 		
AUTOIMMUNE DISEASE The	essential	characteristic	of	autoimmunity	is	the	immunological	attack	on	self-tissue	[1].	What	triggers	the	immune	system	to	mount	a	specific	response	against	self-antigens	is	largely	unknown,	but	the	importance	of	both	environmental	and	genetic	factors,	especially	HLA	genotype,	have	been	demonstrated.	The	incidence	of	different	autoimmune	diseases	varies	throughout	the	world,	but	collectively	affect	about	5%	of	the	population	[2-4].	It	is	a	diverse	group	of	clinically	distinct	entities,	and	the	amount	of	evidence	supporting	an	autoimmune	aetiology	varies	between	different	diseases	[5].		To	investigate	whether	a	disease	is	autoimmune	is	easier	said	than	done.	A	number	of	criteria	can	be	evaluated,	but	perhaps	the	most	obvious	autoimmune	feature	is	pathogenic	autoantibodies.	Transfer	of	disease	by	passive	immunization	gives	direct	evidence	of	autoimmunity	[6].	For	obvious	reasons,	transfer	of	pathogenic	autoantibodies	between	humans	is	avoided	but	it	sometimes	occurs	as	an	experiment	of	nature.	Transplacental	transmission	of	IgG	occurs	in	every	pregnancy	and	can	transfer	autoantibody-mediated	diseases	from	mother	to	foetus.	That	is	the	case	with	thyrotropin	receptor	antibodies	in	neonatal	Graves’	disease	and	acetylcholine	receptor	antibodies	in	neonatal	myasthenia	gravis	[7].	Transfer	of	autoantibodies	across	species	can	also	demonstrate	their	pathogenic	effect	[8].	Autoantibodies	in	most	autoimmune	diseases,	however,	are	not	pathogenic	in	themselves,	and	the	tissue	damage	is	believed	to	be	inflicted	by	antigen-specific	T	cells.	In	line	with	this,	Addison’s	disease	and	type	1	diabetes	mellitus	are	not	transferred	from	afflicted	mothers	to	their	foetuses,	despite	placental	transmission	of	autoantibodies	against	21-hydroxylase	and	GAD-65,	respectively.	Even	in	the	absence	of	pathogenic	autoantibodies,	it	is	possible	to	find	indirect	evidence	of	an	autoimmune	aetiology.	An	early	model	dates	back	to	the	nineteen-fifties	and	resemble	Koch’s	postulates	for	infectious	disease	[9].	Like	a	microbial	agent	can	be	identified	and	employed	to	transfer	disease	between	individuals,	Witebsky	suggested	analogous	criteria	to	support	an	autoimmune	aetiology:	the	B	cell	autoantigen	should	be	identified,	and	immunization	with	the	same	antigen	in	experimental	animals	should	reproduce	both	the	disease	and	the	autoantibodies.	The	mere	demonstration	autoantibodies	or	self-reactive	T	cells	targeting	the	affected	organs,	also	provide	indirect	evidence	of	autoimmunity	[10,	11].	The	suspicion	of	autoimmune	disease	aetiology	can	also	be	raised	by	circumstantial	evidence	such	as	beneficial	response	to	immunosuppressive	therapy	or	a	strong	association	to	HLA	genotype	[5].	Infiltration	of	immune	cells	in	affected	tissues	are	also	common	findings,	although	not	specific	for	
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autoimmunity	[12].	Concomitance	with	other	autoimmune	diseases	in	the	same	patient	or	the	same	family	is	typical.	An	autoimmune	disease	can	be	classified	according	to	its	distribution	as	either	systemic,	exemplified	by	SLE,	or	organ-specific	in	for	instance	autoimmune	Addison’s	disease	and	type	1	diabetes	mellitus	[13].	Systemic	diseases	can	for	long	be	limited	to	a	single	tissue	but	they	can	also	flare	with	multiorgan	involvement	and	fever.	Autoantibodies	in	organ-specific	autoimmune	diseases	are	typically	directed	against	tissue-restricted	proteins,	whereas	in	systemic	diseases,	they	target	ubiquitously	expressed	proteins.	The	group	of	organ-specific	autoimmune	diseases	can	be	further	subdivided	(Table	1).	In	destructive	autoimmune	diseases	such	as	type	1	diabetes	and	Addison’s	disease	the	islet	cells	and	adrenal	cortex,	respectively,	are	permanently	destroyed	and	the	essential	hormones	they	produce	are	lost.	In	contrast,	the	non-destructive	autoimmune	diseases	can	disrupt	the	function	of	cell	surface	proteins	without	destroying	the	target	tissue.	In	Graves’	disease,	autoantibodies	stimulate	the	TSH-receptor	resulting	in	thyrotoxicosis,	while	in	myasthenia	gravis,	autoantibodies	inhibit	the	acetylcholine	receptor	in	the	neuromuscular	junction	resulting	in	muscle	weakness.	
Table 1. Characteristics of organ-specific autoimmune diseases. 
 Example of diseases B cell autoantigen 
Destructive autoimmunity Addison’s disease 21-hydoxylase 
 Type 1 diabetes Glutamate decarboxylase-65 
 Autoimmune thyroiditis Thyroid peroxidase 
   
Non-destructive autoimmunity Graves’ disease TSH receptor 
 Myasthenia gravis Acetylcholine receptor 
 Limbic NMDA receptor encephalitis NMDA receptor 	 	 		
THE GENETIC BACKGROUND OF AUTOIMMUNITY Autoimmune	diseases	sometimes	co-occur	in	families,	even	across	diseases,	and	the	increased	incidence	is	far	higher	than	expected	by	chance	[14].	For	example,	ulcerative	colitis	often	co-occurs	with	Crohn’s	disease	[15],	and	vitiligo	with	both	coeliac	disease	and	type	1	diabetes	[15].	More	than	half	of	patients	with	Addison’s	disease	have	a	concomitant	autoimmune	disease	with	autoimmune	thyroid	disease	being	most	frequent	followed	by	autoimmune	atrophic	gastritis	with	B12	deficiency,	type	1	diabetes,	premature	ovarian	insufficiency	in	women,	and	vitiligo	[16,	17].	The	aggregation	in	families	and	individuals	suggests	that	risk	factors	are	shared	between	family	members,	and	between	diseases	[3].	Even	though	not	much	is	known	in	detail,	autoimmune	disease	is	described	as	the	result	of	interaction	of	both	genetic	susceptibility	factors	and	
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environmental	triggers	[18].	Environmental	risk	factors	include	for	instance	iodine	intake	associated	with	an	increased	incidence	of	autoimmune	thyroiditis	and	certain	influenza	vaccinations	associated	with	narcolepsy	[19,	20].	Gene-environment	interactions	have	also	been	demonstrated,	for	example	smoking	with	HLA	haplotypes	and	PTPN22	in	multiple	sclerosis	and	rheumatoid	arthritis	[21-23].		In	addition	to	shared	environment,	shared	genetic	risk	factors	lay	the	foundation	for	co-occurrence	of	diseases.	However,	although	common	autoimmune	diseases	co-occur	within	families	and	share	genetic	risk	factors,	they	show	no	signs	of	Mendelian	inheritance	[2].	The	genetic	variants	associated	to	disease	are	found	in	both	affected	and	unaffected	individuals.	This	ambigous	link	between	genotype	and	phenotype	is	typical	of	complex	traits	and	has	several	causes.	For	instance,	genes	involved	in	the	same	biochemical	pathway	may	be	distributed	throughout	the	genome,	and	a	mutation	in	a	single	one	of	them	may	increase	disease	susceptibility	in	individual	patients.	Other	diseases	may	require	the	joint	effects	of	a	number	of	variants	in	several	genes	to	manifest;	no	single	mutation	is	enough	to	cause	the	disease	and	no	single	mutation	is	strictly	required.	
DISSECTING INHERITANCE IN COMPLEX TRAITS Linking	disease	traits	to	genomic	markers	begun	more	than	a	hundred	years	ago	[24],	and	the	recognition	of	naturally	occurring	DNA	variation	was	a	breakthrough	in	the	number	of	available	markers	[25].	Loci	conferring	the	highest	disease-risks	are	the	easiest	to	discover	and	the	HLA	complex	was	consistently	linked	to	autoimmune	disease	well	before	the	advent	of	high	throughput	genotyping,	using	linkage	analysis	in	family-based	studies	[26,	27].	Genomic	linkage	studies	take	advantage	of	the	fact	that	alleles	on	the	same	chromosome	are	more	likely	to	be	inherited	together	if	they	are	located	close	to	each	other	[28].	Throughout	the	genome,	selected	markers	are	genotyped	in	family	members,	with	and	without	the	trait	of	interest.	By	studying	the	extent	that	alleles	co-segregate	with	the	disease	in	a	pedigree,	linkage	between	a	genomic	region	and	disease	is	demonstrated.	Typically,	the	resultant	regions	are	large	since	the	resolution	depends	on	the	number	of	recombination	events,	and	the	size	of	the	studied	families.	Linkage	analysis	is	most	suitable	for	simple	Mendelian	traits	but	has	also	successfully	linked	some	regions	to	complex	traits,	such	as	NOD2	to	Crohn’s	disease	[29,	30].	In	contrast	to	linkage	analysis,	association	studies	do	not	rely	on	pedigrees	and	are	often	preferred	for	studies	of	complex	traits.	They	simply	compare	the	frequencies	of	an	allele	or	a	genotype	in	affected	patients	and	healthy	controls	[31].	Hence,	a	simple	contingency	table	is	all	it	takes	to	summarize	the	data	for	the	two	study	groups	[32].	Alleles	or	genotypes	occurring	significantly	more	frequently	in	patients	are	associated	with	disease.	Rather	than	cosegregation	in	families,	association	studies	depend	on	unrelated	individuals	to	provide	unbiased	allele	frequency	estimates.	Carefully	chosen	case	and	control	groups	are	essential	in	order	to	avoid	the	otherwise	reliable	
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disappointment	of	spurious	associations	[31].	Studies	of	single	candidate-genes	or	small	case	groups	are	prone	to	false	associations	caused	by	both	population	substructures	and	chance,	and	results	have	often	been	difficult	to	reproduce	in	larger	well-powered	studies	[33].	Nonetheless,	the	candidate-gene	approach	has	yielded	important	findings,	such	as	the	associations	of	CTLA4	and	PTPN22	to	several	autoimmune	diseases	including	autoimmune	Addison’s	disease	(Table	2)	[34-38].	With	high-throughput	genotyping,	however,	investigators	can	include	markers	from	the	entire	genome	and	are	no	longer	limited	to	single	candidate	genes.	Studies	covering	large	proportions	of	the	genome	are	less	biased	in	this	sense	and	enable	novel	discoveries.		
Table 2. Example of risk loci that have been associated to several common autoimmune 
diseases, and their function. 
Gene / Region Function 
HLA-DRB1 Expressed on specialized antigen-presenting cells and present peptides from extracellular proteins to T cells. 
CTLA4 Costimulatory molecule transmitting signals from antigen-presenting cells. Inhibits antigen-activated immune responses in T cells. 
IL2RA Receptor for interleukin 2, essential in T cell proliferation and differentiation. 
PTPN22 Lymphoid-specific protein tyrosine phosphatase involved in T cell receptor signalling. 
STAT4 Intracellular signalling molecule mediating responses to interleukin 12 in lymphocytes, controlling the differentiation of T helper cells. 
Immunobase (immunbase.org) and RefSeq (ncbi.nlm.nih.gov/refseq/rsg/) accessed April 11 2018.			Under	the	null	hypothesis,	P	values	follow	a	uniform	distribution.	With	multiple	genetic	markers	studied	in	parallel,	the	risk	of	detecting	associations	due	to	chance	increases,	and	the	statistical	significance	threshold	has	to	be	adjusted	accordingly	(figure	1,	table	3)	[39].	Such	a	correction	can	compensate	for	the	number	of	hypothesis	tests	at	the	expense	of	decreased	statistical	power.	To	maintain	a	sensitivity	for	risk	loci	with	moderate	or	small	effects,	larger	sample	sizes	are	required.	However,	the	simultaneous	study	of	many	independent	markers	is	advantageous	in	other	aspects.	For	instance,	population	substructures	can	be	taken	into	account	when	calculating	the	strength	of	association.	Relatedness	between	subjects	can	be	thought	of	as	their	pairwise	mathematical	distance	measured	across	all	the	dimensions	that	the	genetic	markers	constitute.	With	dimensionality	reduction,	the	distances	between	all	possible	pairs	of	samples	can	be	summarized	to	coordinates,	easy	to	plot	in	two	dimensions	[40].	Typically,	these	plots	may	resemble	a	geographical	map	corresponding	to	the	ancestry	of	the	samples,	and	population	substructures	are	visualised	as	clusters	[41].	By	including	coordinates	as	covariates	in	statistical	models,	population	substructure	can	be	accounted	for	in	multi-marker	genetic	studies	and	reduce	the	risk	of	false	associations.	
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Figure 1. Quantile-quantile plot of 500 P values following a uniform distribution. Critical values are 
depicted according to Bonferroni (BF, red), and Benjamini and Hochberg (B&H, blue). The 95% 
confidence interval is shaded in grey with a white identity line. 
Table 3. Correction for testing 𝒎 hypotheses at the accepted risk 𝜶 of making a type I error, 
conventionally set at 0.05. The false discovery rate depends on the rank (𝒊) of the P-value. 
Error criterion Method Critical value (𝐜) 
Familywise error rate Bonferroni 𝑐 = 	𝛼	/	𝑚 
False discovery rate Benjamini and Hochberg	 𝑐+ = 	𝑖	𝛼	/	𝑚		 	 	Genome-wide	association	studies	(GWAS)	typically	investigate	hundreds	of	thousands	of	SNPs	across	the	genome,	and	are	optimized	to	discover	common	alleles	that	explain	a	significant	proportion	of	the	population	disease	risk	[42].	Hundreds	of	common	variants	have	been	associated	with	autoimmune	diseases	using	GWAS	[43].	Some	associations	are	disease-specific,	for	instance	Thyroid	stimulating	hormone	receptor	in	Graves’	disease	[44]	and	Insulin	in	type	1	diabetes	[3].	Other	associations	are	shared	between	autoimmune	diseases	and	suggest	a	common	genetic	aetiology,	in	line	with	the	familial	clustering	across	individuals	and	diseases	[3,	45-47].	In	fact	more	than	half	of	the	SNPs	associated	to	autoimmune	diseases	in	genome-wide	studies	associate	to	more	than	one	of	the	diseases	[47].	Given	this	large	extent	with	which	genetic	risk	factors	are	shared	between	diseases,	it	is	worth	noting	that	common	genetics	predict	co-occurrence	rather	than	clinical	similarity.	For	instance,	ankylosing	spondylitis	and	rheumatoid	arthritis	both	affect	joints,	but	show	exceptionally	few	shared	risk	loci	for	a	pair	of	autoimmune	
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diseases	[3].	The	most	consistently	associated	locus	across	autoimmune	diseases	is	the	HLA	region,	typically	representing	the	strongest	genetic	risk	factor	[48].	Depending	on	disease,	both	homozygosity	and	heterozygosity	can	confer	the	highest	risks,	and	different	HLA	genes	and	HLA	alleles	show	association	with	different	diseases	[49,	50].	
WHAT HERITABILITY IS AND IS NOT It	is	easier	to	successfully	link	a	genomic	region	to	disease	if	the	disease	at	hand	has	a	high	heritability	[31].	This	popular	statistic	is	defined	as	the	variance	in	the	genotype	divided	by	the	total	variance	in	the	phenotypic	trait,	and	hence	range	from	0	to	1	(Table	4).	For	a	dichotomous	trait	such	as	destructive	autoimmunity,	this	means	that	for	a	given	population	and	a	given	environment,	the	heritability	is	the	proportion	of	disease	liability	that	can	be	attributed	to	genetic	variation.	It	does,	however,	not	tell	us	the	proportion	of	a	trait	that	will	be	inherited	by	the	offspring,	and	a	high	heritability	does	
not	allow	us	to	determine	the	phenotype	from	the	genotype	[51].		
Table 4. Definition of the heritability estimate. ℎ. = 	𝜎0.𝜎1. 	= 	 𝜎0.𝜎2. 	+	𝜎4.		 (1) 
Narrow sense heritability (ℎ.) is defined as a ratio of the additive partition of genotypic 
variance (𝜎0.), and the variance of the observable phenotypes (𝜎1.) [51].	 	
The variance of observable phenotypes can be partitioned into underlying variances of 
genotypes and environment (𝜎4.). 		 	With	the	population	prevalence	taken	into	account,	the	heritability	is	usually	estimated	from	either	the	disease	recurrence	rate	in	close	relatives	(λR),	or	from	disease	concordance	rates	in	identical	and	fraternal	twins	[31,	52].	A	higher	relative	risk	in	closer	relatives	corresponds	to	a	stronger	heritability.	For	instance,	in	a	twin	concordance	study	by	Skov	et	al.	the	heritability	in	Addison’s	disease	in	Sweden	has	been	estimated	to	be	0.97	(95%	CI	0.88–0.99)	[53].	In	this	study,	the	variance	in	environmental	effects	have	had	little	influence	on	total	phenotypic	variance	and	the	ensuing	high	heritability	indicates	a	trait	suitable	for	genetic	study	[31].	Autoimmune	diseases	coinherited	with	Addison’s	disease	have	shown	comparable	results	in	other	populations;	type	1	diabetes	0.69-0.88	and	autoimmune	thyroid	disease	0.79	[54-59].	Even	if,	strictly	speaking,	the	heritability	is	population-specific,	it	is	often	similar	in	different	populations	[51].	The	heritability	reveals	the	relative	importance	of	genes	and	environment	on	the	variation	of	disease	liability.	It	can	also	be	used	to	establish	the	efficiency	of	gene-mapping	studies.		
EFFICACY OF GENETIC ASSOCIATION STUDIES Autoimmune	diseases	have	been	studied	in	GWAS	and	the	discovered	risk	alleles	typically	have	a	small	or	modest	effect	on	disease	liability,	evident	from	an	odds	ratio	
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near	1.	For	instance,	in	autoimmune	thyroid	disease,	SNPs	outside	the	HLA	region	have	odds	ratios	in	the	lower	range;	1.16	–	1.63	[60].	In	type	1	diabetes,	the	range	is	similar;	1.05	–	2.38	[61,	62](Odds	ratios	from	immunobase.org,	accessed	16	March	2018).	Collectively,	GWAS	variants	explain	only	a	minor	fraction	of	the	total	heritability,	and	this	is	a	recurrent	finding	for	several	complex	traits	[42,	63,	64].	The	enrichment	of	genes	expressed	in	certain	cell	types	or	essential	in	certain	pathways,	may	nevertheless	render	biological	hypotheses	[65].	Risk	loci	in	type	1	diabetes,	for	instance,	are	enriched	for	genes	influencing	the	adaptive	immune	response	and	T	cell	differentiation	[66].	The	proportion	of	heritability	that	is	accounted	for	by	the	established	risk	genes	in	Addison’s	disease	has	not	been	determined.	The	power	to	detect	associations	with	tiny	effect	sizes	steadily	increases	with	the	inclusion	of	more	study	subjects.	Even	in	GWAS	comprising	hundreds	of	thousands	of	samples,	however,	the	tiny	effect	sizes	discovered	collectively	explain	less	than	half	of	the	phenotypic	variance	[67,	68]	.	As	the	study	sizes	increase,	the	possible	effect	sizes	in	associations	left	to	discover	decrease,	and	the	total	number	of	loci	necessary	to	associate	in	order	to	explain	the	full	heritability	increases	towards	the	hundreds	or	even	thousands.	Some	researchers	nevertheless	believe	that	the	majority	of	remaining	risk	variants	reside	in	loci	with	tiny	effects,	hiding	in	the	background	of	random	associations	[69].	Others	advocate	that	rare	variants	with	large	effect	sizes	are	the	most	probable	cause	of	the	apparently	missing	heritability	[69].	Whatever	the	case,	undiscovered	genetic	variants	may	still	exist	in	complex	and	repetitive	regions	of	our	genome.	Copy	number	variations	are	often	neglected	in	genetic	studies	but	have	been	associated	with	autoimmune	diseases	such	as	psoriasis	and	Crohn’s	disease	[70,	71].	Rare	structural	variants	can	collectively	make	up	a	substantial	contribution	to	genetic	variation	[72].		
MAKING THE LEAP FROM ASSOCIATION TO CAUSATION More	than	90%	of	the	variants	associated	to	autoimmune	diseases	in	GWAS	reside	outside	of	protein-coding	genes	[46].	They	preferentially	enrich	in	regulatory	regions	active	in	immune	cells	but	rarely	affect	recognizable	transcription	factor	binding	motifs	[46,	73].	For	example,	risk	variants	in	type	1	diabetes	enrich	in	enhancers	active	in	thymus	and	lymphocytes.	whereas	SLE	loci	control	genes	preferentially	expressed	in	B	cells	[62,	73,	74].	Only	a	fragment	of	the	hundreds	of	risk	loci	discovered	in	GWAS	have	had	their	exact	molecular	mechanisms	resolved.	Association	studies	alone	have	a	limited	ability	to	distinguish	causal	variants	from	the	region	associated	to	disease	and	to	discern	the	individual	regulatory	element	that	mediates	risk,	or	the	genes	it	regulates	[69].	Since	the	SNPs	associated	in	a	GWAS	may	affect	genes	other	than	the	one	closest,	eQTLs	overlapping	a	GWAS	hit	can	help	connect	candidate	causal	variants	with	appropriate	risk	genes	[75].	Epigenetic	data	can	also	help	assess	both	which	variants	are	likely	to	be	causal	[76,	77]	,	and	to	identify	the	regulatory	regions	that	mediate	risk	and	the	genes	
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they	control	[78].	Integration	of	genetic	associations	with	expression	patterns	and	epigenetic	data	may	aid	in	the	identification	of	candidate	variants	for	functional	studies	[75,	79-81].	
HIGH THROUGHPUT SEQUENCING The	sequencing	of	the	human	genome	was	facilitated	by	the	advent	of	massive	parallel	sequencing	technology	and	finished	in	year	2001	[82,	83].	High	throughput	sequencing	is	achieved	by	first	shearing	the	DNA	molecules	into	miniscule	pieces,	and	then	sequencing	all	fragments	simultaneously.	Each	parallel	sequencing	experiment	generates	reads,	short	stretches	of	genetic	code	(Table	5).	The	reference	genome	helps	assemble	the	reads	into	contiguous	sequences.	Mismatches	from	the	reference	sequence	are	listed	as	genetic	variants,	and	mostly	represent	natural	variation	or	sequencing	errors.	Among	other	things,	the	final	quality	of	the	variant	calls	is	dependent	on	the	read	depth,	i.e.	the	number	of	times	each	position	of	the	genome	has	been	sequenced	and	successfully	aligned	to	the	reference.	Repetitive	sequences	and	structural	variation	complicate	read	alignment.	To	facilitate	alignment,	DNA	fragments	are	sequenced	from	both	ends,	producing	pairs	of	sequencing	reads.	By	aligning	paired	reads	simultaneously,	on	a	fragment	length	from	each	other,	ambiguous	alignments	are	resolved	in	complicated	regions.	Yet,	in	highly	variable	regions	such	as	the	HLA	region,	alternative	sequencing	technologies,	or	customized	methods	for	aligning	and	variant	calling	are	advisable.		
Table 5. The alignment of sequencing reads to the reference genome enables the 
recognition of genetic variants. Aligned reads that differ from the reference are the basis 
for variant calls. In patients that are heterozygous for a given position, about half of the 
reads are expected to represent each of the two alleles. In this example, the aligned reads 
indicate a position with a heterozygous genotype. The read depth at this position is 7. 
 Unaligned reads Aligned to reference genome 
Sequencing reads 
ATGGCATTGCAA 
TGGCATTGCAATTTG 
AGATGGTATTG 
GATGGCATTGCAA 
GCATTGCAATTTGAC 
ATGGCATTGCAATTT 
AGATGGTATTGCAATTTG 
   ATGGCATTGCAA 
    TGGCATTGCAATTTG 
 AGATGGTATTG 
  GATGGCATTGCAA 
      GCATTGCAATTTGAC 
   ATGGTATTGCAATTT 
 AGATGGTATTGCAATTTG 
Reference genome …AGATGGCATTGCAATTTGAC… …AGATGGCATTGCAATTTGAC… 	   Compared	to	genome-wide	SNP-typing,	sequencing	yields	denser	variant	calls	and	detects	potential	rare	variants.	Sequencing	of	selected	genomic	regions	reduces	costs,	compared	to	a	whole-genome	sequencing,	and	can	be	enabled	through	targeted	enrichment.	Exome	sequencing	is	the	most	common	application.	Targeted	regions	are	physically	captured	when	complementary	probes,	attached	to	solid	support,	are	hybridized	to	the	DNA	samples.	Hybrid	capture	can	handle	thousands	of	selected	sequences	but	a	drawback	is	the	uneven	coverage	of	targeted	regions.	Highly	conserved	
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exons	generally	contain	fewer	variants	than	the	non-coding	regions,	but	more	variants	with	large	effect	on	disease	susceptibility	[84].	Therefore,	exome-sequencing	has	been	the	method	of	choice	for	identification	of	rare	high-impact	variants.		
ADDISON’S DISEASE A	typical	example	of	destructive	autoimmunity	is	autoimmune	Addison’s	disease	(AAD)	[85].	It	is	the	predominating	cause	of	primary	adrenal	insufficiency	and	ultimately	lethal	if	the	essential	adrenal	hormones	cortisol	and	aldosterone	are	not	substituted	[86,	87].	Many	patients	present	with	an	acute	insufficiency	that	requires	cortisol	immediately	[88].	Adrenal	insufficiency	may	be	suspected	in	cases	with	fatigue,	low	blood	pressure,	abdominal	pain,	nausea,	weight	loss	or	hyperpigmentation	of	the	skin,	and	diagnosed	in	patients	with	low	morning	serum	cortisol	and	elevated	plasma	adrenocorticotropic	hormone	(ACTH)	[87,	89].	In	case	of	uncertainty,	inadequate	cortisol	levels	after	corticotropin	stimulation	gives	the	diagnosis.	Autoimmune	aetiology	is	confirmed	with	the	presence	of	21-hydroxylase	autoantibodies	[10,	87].	The	onset	of	AAD	is	typically	occurring	in	the	third	to	fifth	decade	of	life	and	slightly	more	women	are	affected	(60%-65%)	[16,	90].	The	prevalence	in	Caucasian	populations	ranges	from	87	to	221	per	million.	[16,	91-97].	It	appears	more	often	in	families	than	what	would	be	expected	by	chance	alone	[98-104],	in	line	with	a	high	heritability	[53].	The	majority	of	AAD	patients	have	other	concomitant	tissue-specific	autoimmune	diseases	such	as	type	1	diabetes,	autoimmune	thyroid	disease,	or	pernicious	anaemia,	reflecting	shared	risk	factors	[17].	Apart	from	the	well-characterized	association	to	the	HLA	complex,	little	has	been	known	about	the	genetic	variants	that	contribute	to	disease	development	[105].	Until	now,	candidate	gene	studies	have	linked	genes	first	implicated	in	other	autoimmune	diseases	to	AAD	(Table	6)	[105,	106].	The	rarity	of	AAD	has,	however,	made	extensive	unbiased	genome-wide	association	studies	unfeasible.	
Table 6. Genes associated to autoimmune Addison’s disease in at least two independent 
candidate-gene studies. 
Gene Study design Reference 
CTLA4 Candidate gene studies  [37, 107-109] 
CYP27B1 Candidate gene studies  [110, 111] 
NLRP1 Candidate gene studies  [112, 113] 
PTPN22 Candidate gene studies  [38, 114-116] 
 The	gap	between	disease	associations	and	mechanistic	knowledge	is	dramatically	shortened	when	changing	focus	from	diseases	with	complex	inheritance	to	diseases	with	monogenic	inheritance.	Identification	of	causal	genes	in	rare	monogenic	autoimmune	diseases	has	enabled	the	characterization	of	both	normal	and	pathologic	immune	system	mechanisms.	
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MONOGENIC AUTOIMMUNE DISEASE Monogenic	autoimmune	syndromes	have	yielded	valuable	insight	into	our	immune	system	and	its	dysregulation	in	autoimmune	disease.	For	instance,	research	on	autoimmune	polyendocrine	syndrome	type	1	(APS1)	has	expanded	our	knowledge	about	central	immune	tolerance,	enforced	by	the	thymus	[117].	Likewise,	peripheral	immune	tolerance	has	been	studied	in	patients	with	monogenic	defects	in	regulatory	T	cells.		
Table 7. Rare monogenic diseases have revealed highly penetrant disruptive mutations in 
critical immune genes. GWA studies point out that common alleles in the same loci have 
been associated to common autoimmune diseases. 
Monogenic autoimmune 
disease Affected gene1 
Complex autoimmune diseases 
associated in GWAS2 
Autoimmune polyendocrine 
syndrome type 1 AIRE RA 
Immune dysregulation due to CTLA4-
mutation CTLA4 AA, AITD, CD, CoD, MG, RA, T1DM, UC 
Autoimmune lymphoproliferative 
syndrome FAS JIA 
Immunodysregulation 
polyendocrinopathy, enteropathy, X-
linked 
FOXP3 - 
Immunodeficiency 41 with 
lymphoproliferation and autoimmunity IL2RA AA, AITD, CD, JIA, MS, RA, T1DM, UC, VIT 
Multisystem autoimmune disease with 
facial dysmorphism ITCH  UC 
Common variable immunodeficiency 
8 with autoimmunity LRBA - 
Immunodeficiency 31C STAT1 CoD, CD, JIA, MS, PBC, RA, SLE, SS, UC 
Infancy-onset multisystem 
autoimmune disease STAT3 CD, MS, PSO, UC 
1[118-122]. 2Immunobase (immunbase.org) and GWAS catalog (ebi.ac.uk), accessed March 16 2018. 
Abbreviations: AA Alopecia areata, AAD Autoimmune Addison's disease, AITD Autoimmune thyroid 
disease, AS Ankylosing spondylitis, CD Crohn’s disease, CoD Coeliac disease, JIA Juvenile idiopathic 
arthritis, MG Myasthenia gravis, MS Multiple sclerosis, PBC Primary biliary cirrhosis, PSO Psoriasis, RA 
Rheumatoid arthritis, SLE Systemic lupus erythematosus, SS Sjögren's syndrome, T1DM Type 1 diabetes 
mellitus, UC Ulcerative colitis, VIT Vitiligo. 	Patients	with	APS1	are	classically	affected	by	a	triad	of	clinical	manifestations:	chronic	mucocutaneous	candidiasis,	hypoparathyroidism	and	adrenal	insufficiency	[123,	124].	Common	manifestations	also	include	autoimmune	forms	of	diabetes,	ovarian	failure,	alopecia	and	lung	disease	[125].	This	wide	spectrum	of	disease	components	is	caused	by	
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dysfunction	of	the	AIRE	protein,	encoded	by	a	single	susceptibility	gene	with	the	same	name	[118,	119].	AIRE	acts	as	a	transcriptional	regulator	in	thymic	cells	and	it	is	a	key	factor	in	T	cell	development	[117].	With	a	normal	AIRE	function,	proteins	with	an	otherwise	tissue-restricted	exoression	are	ectopically	expressed	in	the	thymus.	This	is	instrumental	to	the	negative	selection	of	developing	T	cells.	With	a	defective	AIRE,	ectopic	expression	of	proteins	in	the	thymus	is	disrupted	and	potential	autoreactive	T	cells	evade	apoptosis	[117,	126,	127].	Although	traditionally	reported	as	a	recessive	disorder,	dominant	missense	mutations	have	recently	been	described	in	a	few	families,	with	a	less	severe	phenotype	[128-131].	The	prevalence	of	APS1	is	roughly	1:100	000	but	more	common	in	some	countries,	primarily	due	to	founder	effects	and	relative	isolation	[85,	132].	The	loss	of	AIRE	function	causes	autoimmunity	in	multiple	but	defined	tissues,	as	evident	from	both	lymphocytic	infiltrates	and	autoantibodies	[133,	134].	In	contrast	to	APS1	and	central	tolerance,	IPEX	(immunodysregulation,	polyendocrinopathy,	and	enteropathy,	X-linked)	is	an	autoimmune	syndrome	that	has	yielded	insight	in	peripheral	immune	tolerance.	IPEX	is	an	X-linked	recessive	disorder	typically	presenting	in	infancy	with	severe	enteropathy	[135].	Patients	may	also	acquire	additional	manifestations	including	eczematous	dermatitis	or	autoimmune	forms	of	diabetes,	thyroid	disease,	haemolytic	anaemia,	hepatitis	and	nephritis	[136,	137].	Identification	of	the	causing	gene,	FOXP3	[138-140],	has	been	key	to	understanding	the	development	of	regulatory	T	cells.	Regulatory	T	cells	are	essential	upholders	of	peripheral	self-tolerance,	and	FOXP3	a	transcription	factor	critical	for	their	differentiation	and	function	[141,	142].	The	lack	of	regulatory	T	cells	in	IPEX	syndrome	causes	a	loss	of	peripheral	tolerance	and	autoimmunity	in	affected	patients	[120,	143-145].	This	makes	IPEX	a	unique	model	for	the	study	of	peripheral	immune	tolerance.		Several	other	immune	genes	have	been	implicated	in	monogenic	autoimmunity	and	one	can	speculate	that	additional	disorders	are	yet	to	be	discovered	(Table	7).	Many	genes	underlying	monogenic	immune	defects	are	also	associated	with	common	autoimmune	diseases,	even	though	the	pathoetiology	in	the	monogenic	disease	may	differ	from	their	polygenic	counterparts	[120].	
IDENTIFICATION OF NOVEL AUTOANTIGENS Traditionally,	B-cell	autoantigens	in	autoimmune	diseases	have	been	identified	using	western	blot	of	a	tissue	homogenate	or	screening	of	cDNA	libraries,	both	prepared	from	healthy	tissue	representing	the	organ	under	autoimmune	attack.	These	methods	have	been	utilized	in	common	autoimmune	diseases	such	as	Addison’s	disease	[10]	and	type	1	diabetes	[146],	as	well	as	in	APS1	[147-150]	and	IPEX	[151-154].	However,	technical	developments	have	enabled	novel	explorative	approaches	for	autoantigen	discovery.	First	developed	for	genetic	studies,	the	technology	for	printing	and	scanning	DNA	microarrays	has	subsequently	been	adapted	for	construction	of	protein	microarrays	
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[155-157].	With	the	application	of	protein	arrays,	thousands	of	proteins	can	be	screened	in	parallel	for	autoantibodies.		
	
Figure 2. A protein array printed on a microscopy slide. A section of the corresponding scanned 
image is enlarged and presented to the right.	The	first	commercially	available	human	proteome	array,	ProtoArray®,	contains	more	than	9000	full-length	human	proteins	(figure	2).	Expressed	as	GST-fusion	proteins	using	baculovirus	vectors	and	insect	cells,	the	proteins	are	printed	in	duplicates	on	glass	slides	coated	with	nitrocellulose.	By	probing	protein	arrays	with	serum	samples,	potential	autoantibodies	can	interact	with	their	target	proteins.	Fluorescence	labelled	anti	human-IgG	are	then	used	to	detect	the	autoantibodies	and	anti-GST	to	visualise	the	entire	set	of	tagged	proteins.	The	scanned	fluorescence	images	are	aligned	to	a	grid	that	enables	data	extraction	and	integration	with	protein	information.	By	exploring	autoantibodies	in	APS1	sera,	that	have	many	well-established	autoantigens,	Landegren	et	al.	proved	the	reliability	of	protein	arrays	and	their	unprecedented	capacity	in	discovering	novel	autoantigens	in	organ-specific	autoimmune	disease	[133,	158].			
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AIMS 		The	aim	of	this	thesis	was	to	characterize	tissue-specific	autoimmune	disease,	both	in	terms	of	genetic	risk	factors	and	serological	biomarkers.		Our	specific	aims	were	to:	-	Identify	genetic	risk	loci	in	autoimmune	Addison’s	disease	(Paper	I	and	II).		-	Evaluate	the	usefulness	of	cytokine	autoantibodies	in	screening	for	APS1	patients	among	patients	diagnosed	with	Addison’s	disease	(Paper	III).		-	Decipher	peripheral	immune	tolerance	mechanisms	by	investigating	autoantibodies	in	IPEX	syndrome	(Paper	IV).			
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MATERIALS AND METHODS 		Brief	overviews	of	the	materials	and	methods	most	central	to	this	thesis	are	described	in	this	section.	Detailed	descriptions	are	found	in	the	corresponding	papers.	
STUDY PARTICIPANTS The	Swedish	Addison	Registry	was	started	in	2009	to	enable	comprehensive	studies	on	Addison’s	disease	patients.	It	is	estimated	to	constitute	more	than	70%	of	all	putative	patients	with	Addison’s	disease	in	Sweden	[91].	All	included	patients	have	been	characterized	both	clinically	and	serologically,	and	about	90%	have	the	autoimmune	pathoetiology	confirmed	with	positive	21-hydroxylase	autoantibodies	[17].		IPEX	syndrome	is	a	rare	disease	and	collections	of	samples	are	typically	small.	We	have	included	IPEX	patients	from	collaborators	in	Germany,	the	USA,	and	Italy.	The	majority	of	control	subjects	were	retrieved	from	blood	donors	and	the	remainder	from	directed	sampling	of	healthy	individuals.	
NEXT GENERATION SEQUENCING DNA	was	extracted	from	whole	blood	EDTA	and	sonicated	to	fragments	of	400	base	pairs	(bp)	for	sequencing	library	preparation.	Pools	of	eight	samples	were	used	for	hybrid	capture	and	sequenced	with	100-bp	paired-end	reads	using	Illumina	HiSeq	2500.	Samples	with	a	mean	target	coverage	of	less	than	10×	were	resequenced.	Sequencing	reads	were	mapped	to	hg19	with	BWA	[159]	and	processed	with	a	pipeline	adapted	from	genome	analysis	toolkit	(GATK)	best	practices	[160,	161].		
PROTEIN ARRAY SCREENING We	used	commercial	protein	microarrays	to	screen	serum	samples	for	autoantibodies	(ProtoArray®;	Thermo	Fisher).	Protein	arrays	were	incubated	stepwise	with	serum	sample	diluted	1:2000,	and	subsequently	with	fluorescently	labelled	detection	reagents,	according	to	the	manufacturers	protocol.	Arrays	were	scanned	in	a	microarray	scanner	(LuxScan	HT24;	CapitalBio)	and	data	was	extracted	using	acquisition	software	(GenePix	Pro	v6.1;	Molecular	Devices).	
RADIO-LIGAND BINDING ASSAY To	assay	serum	samples	for	autoantibodies,	we	used	recombinant	proteins	marked	with	a	radioactive	tracer.	Full-length	cDNA	clones	encoding	genes	of	interest	were	subcloned	into	expression	vectors,	transcribed	and	translated	in	vitro,	thereby	enabling	the	incorporation	of	35S-methionine.	Radiolabelled	antigens	were	incubated	with	serum	
 16	
samples,	and	immune	complexes	were	precipitated	with	protein-A	Sepharose	and	96-well	filter	plates.	Radioactive	decay	was	measured	in	a	liquid	scintillation	counter	(Wallac	Microbeta	1450;	PerkinElmer).					
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RESULTS AND DISCUSSION 		
PAPER I Sporadic	autoimmune	Addison’s	disease	is	caused	by	an	autoimmune	destruction	of	the	adrenal	cortex,	but	little	is	known	about	the	aetiology	[162].	Despite	the	high	heritability,	no	large-scale	genetic	studies	have	been	undertaken	to	explore	its	genetic	background.	To	improve	our	knowledge	about	genetic	risk	factors,	we	made	a	comprehensive	sequencing	study	of	patients	with	autoimmune	Addison’s	disease.	The	Swedish	Addison	Registry	is	the	world’s	largest	biobank	of	primary	adrenal	failure	and	enabled	the	inclusion	of	700	well-characterized	cases.	As	a	control	group,	1501	healthy	Swedish	blood	donors	were	also	included.	We	developed	a	capture	array	for	targeted	sequencing	of	a	wide	range	of	genes	and	their	regulatory	elements.	Genes	known	to	be	involved	in	basic	immune	functions,	inflammation,	or	autoimmune	disease,	were	included	as	well	as	additional	genes	involved	in	associated	immune	pathways.	Genes	causing	congenital	adrenal	insufficiency	were	also	targeted.	Besides	protein	coding	exons,	we	targeted	the	untranslated	regions	of	gene	transcripts,	the	region	surrounding	the	transcription	start	site,	as	well	as	highly	conserved	elements	in	the	surrounding	100	kb	of	the	gene	boundaries.	The	conserved	elements	were	identified	using	genealogical	data	from	29	mammals	[163].	Among	other	measures	taken	to	avoid	false	associations,	we	defined	the	phenotype	thoroughly.	We	excluded	cases	where	other	causes	of	adrenal	failure	than	sporadic	autoimmune	Addison’s	disease	could	be	suspected	(n=173),	including	cases	that	did	not	test	positive	for	21-hydroxylase	autoantibodies	in	two	assays,	performed	at	two	different	laboratories.	Cases	with	autoantibodies	against	interferon-𝛼	and	interleukin-22,	indicative	of	monogenic	autoimmunity	syndromes,	were	also	excluded	[164,	165].	Our	bioinformatic	processing	pipeline	was	set	up	using	the	GATK,	according	to	the	best	practices	recommendations.	Based	on	the	resulting	genotypes,	we	could	estimate	ancestry	and	relatedness	of	both	cases	and	controls.	Predicted	non-European	samples	and	first-degree	relatives	were	excluded	(n=25)	in	order	to	improve	case	group	homogeneity	and	independence	of	study	subjects.	Additional	quality	control	parameters,	including	overall	heterozygosity,	X-chromosome	heterozygosity	and	singleton	counts,	were	used	to	indicate	low	DNA	quality,	batch	effects	and	contamination	of	samples.	Taken	together,	479	cases	and	1394	controls	remained	for	association	analyses	after	quality	control.	
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To	associate	common	single	nucleotide	variants	with	disease,	we	calculated	a	logistic	regression	model	for	each	of	the	103	120	variants	with	a	minor	allele	frequency	of	1%	or	more.	Coordinates	from	multidimensional	scaling	were	included	as	covariates	to	account	for	population	substructures,	and	genomic	control	was	applied	to	compensate	for	residual	inflation	of	the	test	statistic	[166].	To	control	for	multiple	testing,	a	traditional	GWAS	significance	level	was	adopted;	P	=	5	×	10-8.	At	this	level	of	significance,	two	associated	loci	were	discovered	on	chromosome	6	(figure	3).	We	identified	the	gene	BACH2	as	a	novel	risk	locus	in	autoimmune	Addison’s	disease	(rs62408233-A,	OR	=	2.01	(1.71–2.37),	P	=	1.66	×	10-15,	MAF	0.46/0.29	in	cases/controls),	and	found	two	signals	of	association	in	the	HLA	region	(rs41315836-G,	OR	=	0.20	(0.13–0.29),	P	=	5.73	×	10-16;	rs17221059-A,	OR	=	2.29	(1.84–2.84),	P	=	9.59	×	10-13.	BACH2	had	previously	been	associated	to	other	organ-specific	autoimmune	diseases	[167-171].	Therefore,	we	calculated	a	new	logistic	regression	using	only	cases	with	isolated	Addison’s	disease	(n=119),	and	the	association	in	BACH2	remained	statistically	significant	(P	=	3.9	×	10-8).	In	conclusion,	BACH2	was	associated	to	Addison’s	disease	independently	of	the	many	autoimmune	comorbidities	present	in	the	case	group	as	a	whole.	
	
Figure 3. A novel risk locus in Addison’s disease was identified on chromosome 6. The two peaks 
correspond to HLA (left), and BACH2 (right). Reprinted with permission from Journal of Internal 
Medicine	[172]. The	associated	SNPs	in	BACH2	were	all	in	linkage	disequilibrium	with	each	other	complicating	further	dissection	of	the	associated	region.	They	were	all	located	within	the	untranslated	region	beginning	the	gene	transcript	(5’	UTR),	which	potentially	contains	regulatory	elements.	In	fact,	several	of	the	associated	SNPs	had	already	been	linked	to	the	expression	of	BACH2	in	systematic	eQTL	studies	[173].	BACH2	encodes	a	transcription	factor	that	operates	in	lymphocytes.	It	is	an	important	regulator	of	antibody	class	switching	and	production	in	B	cells	[174,	175].	Although	not	crucial	for	T	cell	development	in	the	thymus,	it	is	indispensable	for	a	normal	T	cell	differentiation	in	
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the	periphery.	With	aberrant	BACH2	function,	the	balance	between	lineages	of	helper	T	cells	are	disrupted	at	the	expense	of	regulatory	T	cells	[176,	177].	BACH2	binds	to	the	same	DNA	motifs	as	the	AP-1	transcription	factors,	and	by	antagonizing	their	activating	signals,	BACH2	can	prevent	the	terminal	differentiation	of	cytotoxic	T	cells	[176,	178].		
BACH2	has	been	associated	to	a	number	of	common	autoimmune	diseases	with	varying	impact,	summarized	in	table	8.	Ordered	by	decreasing	odds	ratio,	BACH2	has	a	large	effect	size	in	Addison’s	disease	and	in	coinherited	diseases,	such	as	autoimmune	thyroid	disease	and	type	1	diabetes.	This	is	perfectly	in	line	with	the	high	co-occurrence	observed	for	these	disorders	in	patients	with	Addison’s	disease.	
Table 8. Common genetic markers in BACH2 associated with common autoimmune 
disesases1, including our results for Addison’s disease. 
Disease Top associated marker Alleles Odds ratio 
Autoimmune Addison’s disease rs62408233 G>A 2.01 
Autoimmune thyroid disease rs72928038 G>A 1.23 
Primary sclerosing cholangitis rs56258221 A>G 1.23 
Type 1 diabetes mellitus rs72928038 G>A 1.20 
Vitiligo rs3757247 G>A 1.20 
Type 1 diabetes mellitus rs597325 A>G 1.18 
Ankylosing spondylitis rs17765610 A>G 1.15 
Multiple sclerosis rs72928038 G>A 1.14 
Coeliac disease rs10806425 C>A 1.13 
Rheumatoid arthritis rs72928038 G>A 1.13 
Coeliac disease rs7753008 T>C 1.10 
Multiple sclerosis rs12212193 A>G 1.09 
Crohn’s disease rs1847472 T>G 1.08 
1Immunobase (immunbase.org) and GWAS catalog (ebi.ac.uk), accessed March 16, 2018. To	associate	rare	alleles	with	complex	traits	typically	requires	large	sample	sets,	but	can	be	facilitated	by	evaluating	aggregates	of	rare	alleles	collectively	[179].	We	therefore	performed	a	gene-based	association	test	including	variants	with	minor	allele	frequencies	of	1%	or	less.	However,	no	additional	risk	loci	were	revealed	by	analysis	of	rare	variants.	Similar	to	other	autoimmune	diseases,	Addison's	disease	has	been	associated	to	certain	HLA	haplotypes	[180].	Using	HLA	genotyping	from	de	novo	assembly	of	sequencing	reads,	we	could	confirm	previously	known	associations	to	the	HLA	class	II	region	[181].	The	highest	risk	was	associated	with	the	combination	of	DRB1	alleles	03:01	and	04:04	(OR	=	18	(7.2–46),	P	=	4.9	x	10-12).	The	confirmation	of	previously	established	risk	haplotypes	underlines	the	reliability	of	our	sequencing	results.	This	study	used	high-throughput	sequencing	of	many	of	the	cases	in	the	Swedish	Addison	Registry	to	overcome	limitations	of	studies	of	single	candidate-genes.	By	also	capturing	non-coding	regions,	we	were	able	to	associate	Addison’s	disease	to	
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potentially	regulatory	elements,	which	are	suggested	to	be	major	contributors	to	complex	disease	[182].Given	its	association	to	additional	autoimmune	diseases	and	its	crucial	function	in	lymphocytes,	BACH2	appears	as	a	major	genetic	risk	factor	in	organ-specific	autoimmunity.	Overall,	many	genes	consistently	associated	to	organ-specific	autoimmune	diseases	are	essential	in	lymphocytes.	The	results	of	this	study	are	encouraging	for	future	genetic	studies	in	autoimmune	disease.		
PAPER II In	2016,	allele	counts	from	the	whole	genome	sequencing	of	1000	Swedes	were	made	available	online.	This	enabled	a	good	opportunity	for	a	reanalysis	of	Addison’s	disease	genetics,	a	field	where	large	genetic	studies	are	almost	never	done.	By	means	of	haplotypes	from	the	international	1000	genomes	project,	we	augmented	the	dataset	from	Paper	I	with	additional	imputed	genotypes	and	recalculated	the	associations	with	additional	controls	from	the	1000	Swedish	genomes.	Multiple	risk	loci	have	been	associated	to	Addison’s	disease	in	candidate-gene	studies,	some	of	which	have	never	been	confirmed	in	later	studies.	With	the	most	comprehensive	dataset	in	Addison’s	disease	genetics,	we	first	revisited	previously	suggested	risk	loci	and	replicated	associations	to	CTLA4,	BACH2,	PTPN22	and	CLEC16A	[37,	107-109,	116,	183-185].	In	contrast,	we	failed	to	confirm	CYP27B1	[106],	GATA3	[106],	and	PD-L1	[186]	as	risk	loci	in	our	Swedish	case	group.	Whether	this	discrepancy	is	due	to	risk	factors	varying	between	populations	or	chance	findings	in	small	case-control	studies,	remains	to	be	investigated.	We	next	explored	the	full	set	of	candidate	genes	and	discovered	a	novel	association	encompassing	four	variants	in	the	AIRE	gene	(rs9983695-C,	OR	=	0.37	(0.27-0.52),	P	=	2.1	×	10-8,	MAF	0.04/0.11	in	cases/controls).	The	four	associated	SNPs	were	all	located	in	introns	5	and	8	and	in	strong	linkage	disequilibrium	with	each	other.	Could	the	association	be	due	to	APS1	patients	in	the	study?	At	this	point,	our	case	group	had	already	been	screened	for	clinical	APS1	manifestations,	cytokine	autoantibodies	and	protein-altering	AIRE	mutations,	but	the	novel	association	to	AIRE	still	remained.	Taken	together,	common	genetic	variation	in	AIRE	appeared	to	have	a	role	not	only	in	monogenic,	but	also	in	sporadic	Addison’s	disease	with	complex	inheritance.	This	finding	represents	an	example	of	genes	linked	to	both	a	common	autoimmune	disease	with	complex	inheritance	and	a	rare	autoimmune	disease	with	monogenic	inheritance	(see	Table	7	above)	[120].	In	complex	traits,	multiple	genetic	variants	influence	the	risk	of	developing	disease.	To	investigate	the	distribution	of	risk	variants	in	our	cases	and	controls,	we	counted	risk	alleles	(0,	1	or	2)	at	six	confirmed	risk	loci	(BACH2,	CTLA4,	PTPN22,	CLEC16A,	AIRE,	and	HLA).	As	expected,	the	proportion	of	cases	and	controls	varied	significantly	between	
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risk	allele	strata.	The	dataset	contained	almost	no	controls	with	10-12	risk	alleles,	and	almost	no	cases	with	0-2	risk	alleles.	Looking	in	detail	on	the	risk	alleles	of	each	subject,	they	appeared	to	act	independently	and	with	additive	effects.		In	total,	the	confirmed	six	risk	loci	analysed	in	this	study,	accounted	for	around	7%	of	variance	in	liability	of	autoimmune	Addison’s	disease,	so	the	vast	majority	of	disease	heritability	still	remains	unexplained	[53].	Future	studies	encompassing	the	whole	genome,	larger	case	groups,	and	structural	variants	are	likely	to	account	for	a	larger	proportion	of	heritability,	but	in	general,	even	genome-wide	studies	of	thousands	of	subjects	have	had	limited	success	in	explaining	more	than	half	of	the	heritability	[67,	68].	Hopefully,	our	findings	can	aid	in	understanding	the	genetic	background	of	Addison’s	disease	and	inspire	further	genetic	studies.		
PAPER III A	small	proportion	of	Addison’s	disease	cases	are	caused	by	autoimmune	polyglandular	syndrome	type	1	(APS1)	[124].	Although	early	identification	of	patients	with	APS1	is	vital	given	the	high	risk	of	potentially	lethal	complications,	APS1	has	remained	underdiagnosed	[187].	We	sought	to	evaluate	cytokine	autoantibodies	and	AIRE	sequencing	in	screening	for	APS1	patients	in	an	assorted	Addison’s	disease	cohort.	In	total	677	patients	from	the	Swedish	Addison	Registry	were	screened	for	autoantibodies	against	interleukin-22	and	interferon-α4.	Positive	patients	were	further	investigated	for	clinical	disease	manifestations,	additional	APS1-specific	autoantibodies,	and	AIRE	gene	abnormalities.	
	
Figure 4. Patients with Addison’s disease were screened for autoantibodies against IL-22 and IFN-𝛼4, and compared to healthy controls and patients diagnosed with APS1. 
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Using	radioligand	binding	assays,	we	identified	17	patients	positive	for	interleukin-22	and/or	interferon-α4,	nine	of	which	were	already	diagnosed	with	APS1	(figure	4).	Sequencing	confirmed	typical	APS1-causing	AIRE	mutations	in	the	nine	patients	with	established	APS1	diagnosis.	Of	the	additional	eight	patients	positive	for	cytokine	autoantibodies,	four	fulfilled	clinical	criteria	for	APS1,	and	hence	four	new	patients	with	APS1	were	identified	using	autoantibody	screening.	Investigation	of	the	AIRE	gene	in	the	four	newly	diagnosed	patients	revealed	disease-causing	mutations	in	all	four	patients.	One	of	the	patients	had	none	of	the	previously	described	missense,	splice	site	or	frameshift	mutations.	In	contrast,	copy	number	analysis	of	the	next	generation	sequencing	data	revealed	a	deletion	of	the	first	eight	exons	of	AIRE	(figure	5).	Using	PCR,	the	deletion	could	be	confirmed	in	homozygosity	in	the	same	patient,	as	well	as	in	heterozygosity	in	three	of	the	other	APS1-patients.	This	finding	emphasizes	that	copy	number	variations	should	be	kept	in	mind	if	sequencing	provide	no	or	unexpected	results.	Serologically,	the	four	newly	diagnosed	patients	had	additional	autoantibodies	against	established	autoantigens	specific	for	APS1,	for	instance	against	SOX10,	KCNRG,	and	AADC	[188-190].	This	further	strengthened	the	validity	of	their	new	diagnoses.		
	
Figure 5. Coverage of AIRE is near average for the end of the transcript (right), but about half of 
average in the beginning of the transcript (left), suggesting a heterozygous deletion. The	clinical	APS1	diagnosis	requires	two	of	the	following	three	manifestations:	Addison’s	disease,	primary	hypoparathyroidism,	and	mucocutaneous	candidiasis.	However,	the	genetic	and	serological	aspects	have	enriched	our	understanding	of	APS1	beyond	the	clinical	criteria.	Overall,	our	study	showed	that	additional	APS1	patients	can	be	found	using	serological	screening	of	patients	with	Addison’s	disease.	Besides	the	potential	importance	of	the	diagnosis	for	the	four	newly	identified	APS1	patients,	we	hope	that	future	APS1	patients	will	benefit	from	the	early	recognition	enabled	with	autoantibody	screening.		
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PAPER IV Regulatory	T	cells	depend	on	the	transcription	factor	FOXP3	for	their	normal	function	in	peripheral	immune	tolerance	[191,	192].	In	IPEX	syndrome,	caused	by	FOXP3	mutations,	regulatory	T	cells	are	dysfunctional	and	affected	patients	suffer	from	multi-organ	autoimmunity	[143-145].	Type	1	diabetes	and	severe	enteritis	are	typical	manifestations	and	have	been	associated	with	organ-specific	autoantibodies	[151-153,	193].	We	aimed	at	exploiting	the	humoral	response	in	IPEX	syndrome	for	identifying	novel	autoimmune	targets.	This	would	reveal	what	self-proteins	rely	on	peripheral	tolerance	mediated	by	FOXP3-dependent	regulatory	T	cells.	We	used	commercial	protein	arrays	containing	over	9000	full-length	human	proteins	to	screen	for	autoantibodies	in	14	IPEX	patients	and	24	healthy	controls.	Previously	established	autoantigens	Harmonin	and	GAD65	were	both	confirmed	in	the	screen.	The	results	were	sorted	based	on	case-control	differences	and	the	top	20	targets	were	selected	for	further	investigation.	Besides	GAD65	that	showed	independent	results,	the	top	20	targets	formed	three	clusters	within	which	all	antigens	had	highly	correlated	results:	nuclear	receptors,	enterocyte	antigens,	and	α-interferons.	With	inclusion	of	additional	IPEX	cases	and	healthy	controls,	radioligand	binding	assays	allowed	us	to	confirm	the	reliability	and	specificity	of	our	novel	findings,	as	well	as	to	test	the	autoantibodies	for	cross	reactivity.		Nuclear	receptors	are	present	in	all	animals,	and	the	novel	autoantibodies	were	found	to	be	cross	reactive	against	the	conserved	ligand	binding	domain	[194,	195].	HNF4A	was	the	nuclear	receptor	with	the	strongest	signals	in	the	array	screen.	In	contrast	to	other	nuclear	receptors,	HNF4A	had	a	tissue-specific	expression	profile	limited	to	tissues	affected	in	IPEX	syndrome:	the	gut,	kidney	and	liver.	HNF4A	is	important	in	the	differentiation	of	intestinal	and	renal	epithelia,	and	HNF4A	knockout	mice	are	characterized	by	autoimmune	enteritis	that	mimics	IPEX	enteritis	[196-198].	Most	IPEX	patients	suffer	from	protracted	autoimmune	enteropathy	[199].	It	was	therefore	interesting	to	note	that	the	second	cluster	of	results	contained	the	established	enterocyte	antigen	Harmonin	as	well	as	two	additional	enterocyte	antigens;	ANKS4B	and	ACSL5.	ANKS4B	interacts	with	Harmonin	to	form	a	structural	complex	in	the	microvilli	of	enterocytes,	whereas	ACSL5	controls	proliferation	along	the	crypt-villus	axis	[200-203].	Taken	together,	the	autoantigens	Harmonin,	ANKS4B,	ACSL5	and	HNF4A	all	shared	the	same	expression	pattern.	As	opposed	to	the	tissue-restricted	autoantigens	previously	presented,	the	α-interferons	that	constituted	the	third	cluster	of	results	are	ubiquitous	proteins	expressed	in	response	to	virus	infection	[204].	Autoantibodies	against	α-interferons	have	been	described	in	patients	with	APS1,	thymoma	and	patients	with	RAG-dependent	immunodeficiency	(Recombination-Activating	Genes)	[164,	165,	205,	206].	Hence,	
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interferon	autoantibodies	are	a	common	feature	of	immune	defects	of	different	etiology.	The	cause	of	this	and	the	potential	effects	remains	elusive.	By	consecutive	sampling	of	patients	undergoing	immunosuppressive	treatment	or	hematopoietic	bone	marrow	transplantation	(HSCT),	we	found	that	autoantibody	signals	were	reduced	after	immunosuppressive	treatment	and	depleted	after	transplantation.	Repeated	sampling	may	aid	the	evaluation	of	IPEX	patients	undergoing	HSCT.	We	hope	that	the	findings	in	this	study	can	reflect	the	normal	functions	of	regulatory	T	cells	and	thereby	deepen	our	understanding	of	peripheral	immune	tolerance.	Despite	the	fundamental	defect	in	regulatory	T	cells,	the	autoantibody	repertoire	and	the	clinical	manifestations	in	IPEX	syndrome	appeared	multi-faceted,	yet	organ-specific.	
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CONCLUDING REMARKS AND FUTURE PERSPECTIVES 		This	thesis	investigated	different	aspects	of	organ-specific	autoimmune	disease.	The	genetic	studies	presented	major	novel	risk	loci	in	Addison’s	disease.	BACH2	has	been	associated	to	many	of	the	coinherited	diseases,	whereas	AIRE	has	not	and	is	more	specific	to	Addison’s	disease	in	this	sense.	With	growing	sample	collections,	we	have	now	reached	the	time	when	collaborative	efforts	could	enable	genome-wide	exploration	of	common	variants	in	Addison’s	disease.	The	identification	of	previously	unknown	copy	number	variations	in	AIRE	exemplifies	how	sequencing	can	be	used	to	find	rare	disease-causing	genetic	variants.	Patients	with	early	onset	autoimmune	disease	or	cytokine	autoantibodies	of	unknown	origin	will	be	interesting	candidates	for	future	whole	genome	sequencing	studies.	Autoantibodies	typically	appear	before	the	onset	of	clinical	manifestations	of	autoimmune	disease.	By	utilising	the	high	sensitivity	and	specificity	of	cytokine	autoantibodies,	we	screened	patients	with	Addison’s	disease	and	identified	previously	undiagnosed	APS1	patients.	This	finding	underlines	the	advantages	of	measuring	autoantibodies,	not	only	when	APS1	is	suspected,	but	also	for	screening	purposes.	This	could	prevent	potentially	lethal	complications	of	APS1	before	they	occur.	One	of	the	central	questions	in	autoimmunity	research,	is	what	governs	the	immune	system’s	selection	of	autoantigens.	By	means	of	protein	arrays,	we	comprehensively	explored	the	antigen	repertoire	in	patients	lacking	FOXP3-dependent	regulatory	T	cells.	This	enabled	a	comparison	of	the	antigen	spectra	targeted	by	the	immune	system	in	defects	of	central	(APS1)	and	peripheral	(IPEX)	tolerance	mechanisms.	Characterization	of	the	antigen	selection	in	additional	autoimmune	diseases,	for	instance	congenital	or	paraneoplastic	autoimmune	syndromes,	would	provide	further	insight.		
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